Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.

Official title

A Prospective, Multicentric, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.

Overview

Immunosuppressive therapy of granulomatosis with polyangiitis (GPA, Wegener's) and microscopic polyangiitis (MPA) has transformed the outcome from death to a strong likelihood of disease control and temporary remission. However, most patients have recurrent relapses that lead to damage and require repeated treatment associated with long-term morbidity and death. Rituximab has been shown to be as effective as cyclophosphamide to induce remission and maintenance of remission in severe GPA and MPA patients, with an acceptable safety profile . Although rituximab is becoming the standard of care for maintenance therapy in these patients, relapse still occurs and the optimal duration of prednisone therapy remains debated. On the one hand, most US studies use early withdrawal (6-12 months) because of feared side effects. On the other hand, most European trials propose late withdrawal (\>18 months) given a lower observed relapse rate on long-term low dose glucocorticoids treatment. In a systematic review and meta-analysis, glucocorticoids regimen was the most significant variable explaining the variability between the proportions of ANCA-associated vasculitis patients with relapses. Nevertheless, it was an indirect estimation of treatment effect because of the absence of dedicated randomized trial. This meta-analysis concluded that combined longer-term (i.e. \>12 months) use of low dose prednisone or nonzero glucocorticoids target is associated with a 20% reduction of relapse compared to early withdrawal (i.e. ≤12 months). The relapse rate in patients with early glucocorticoids (10-12 months) withdrawal was provided in two studies and was of 37 and 34%, respectively. By contrast, the relapse rate in patients with late prednisone withdrawal (18-24 months) and receiving rituximab as maintenance treatment was 14% at 24 months in the MAINRITSAN trial. Of note, the decision to withdraw glucocorticoids after 18 months was left to physician's discretion in this study and two thirds of the nonsevere relapses occurred when patients were off prednisone. The trial detailed here is the first prospective trial evaluating the length of glucocorticoid administration as remission adjunctive treatment for patients with GPA or MPA.

Detailed description

Immunosuppressive therapy of granulomatosis with polyangiitis (GPA, Wegener's) and microscopic polyangiitis (MPA) has transformed the outcome from death to a strong likelihood of disease control and temporary remission. However, most patients have recurrent relapses that lead to damage and require repeated treatment associated with long-term morbidity and death.

Rituximab has been shown to be as effective as cyclophosphamide to induce remission and maintenance of remission in severe GPA and MPA patients, with an acceptable safety profile. Although rituximab is becoming the standard of care for maintenance therapy in these patients, relapse still occurs and the optimal duration of prednisone therapy remains debated.

On the one hand, most US studies use early withdrawal (6-12 months) because of feared side effects. On the other hand, most European trials propose late withdrawal (\>18 months) given a lower observed relapse rate on long-term low dose glucocorticoids treatment.

In a systematic review and meta-analysis, glucocorticoids regimen was the most significant variable explaining the variability between the proportions of ANCA-associated vasculitis patients with relapses. Nevertheless, it was an indirect estimation of treatment effect because of the absence of dedicated randomized trial. This meta-analysis concluded that combined longer-term (i.e. \>12 months) use of low dose prednisone or nonzero glucocorticoids target is associated with a 20% reduction of relapse compared to early withdrawal (i.e. ≤12 months).

The relapse rate in patients with early glucocorticoids (10-12 months) withdrawal was provided in two studies and was of 37 and 34%, respectively. By contrast, the relapse rate in patients with late prednisone withdrawal (18-24 months) and receiving rituximab as maintenance treatment was 14% at 24 months in the MAINRITSAN trial. Of note, the decision to withdraw glucocorticoids after 18 months was left to physician's discretion in this study and two thirds of the nonsevere relapses occurred when patients were off prednisone.

The trial detailed here is the first prospective trial evaluating the length of glucocorticoid administration as remission adjunctive treatment for patients with GPA or MPA.

Interventions

• Drug Prednisone 5mg/day extended of 12 additional months
  Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
• Drug Placebo 5mg/day extended of 12 additionnal months.
  1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13

Primary outcome measures

• Relapse-free survival, relapse being defined as BVAS > 0. [Time frame: from Screening to Month 30.]

Secondary outcome measures (11)

• Compare the rate of serious adverse events between Inclusion and Month 30 after randomization [Time frame: from Day 1 to Month 30]
• Compare the rate of predefined severe events related to glucocorticoids between inclusion and Month 30 including osteoporotic fracture and weight gain. [Time frame: From Screening to Month 30]
• To compare the rate of vasculitis relapse at Month 30 [Time frame: from Day 1 to Month 30]
• To compare the prednisone use between inclusion and Month 30 [Time frame: from screening to Month 30]
• To compare variation of the Bone mineral density and markers between inclusion and Month 30 [Time frame: From Screening to Month 30]
• To compare sequelae assessed by BVAS (vasculitis activity) at 30 months [Time frame: From Screening to Month 30.]
• To compare sequelae assessed by the Vasculitis Damage Index (VDI) at 30 months [Time frame: From screening to Month 30.]
• - To compare sequelae assessed by Combined Damage Assessment Index (CDA) at 30 months [Time frame: From Screening to Month 30.]
• - To compare functional disability at Month 30 after randomization (Day 1) in both arms [Time frame: From Day 1 to Month 30.]
• To compare quality of life at Month 30 after randomization (Day 1) in both arms [Time frame: - From Day 1 to Month 30.]
• - To compare healthcare resource utilization at Month 30 after randomization (Day 1) in both arms [Time frame: From Day 1 to Month 30.]

Eligibility criteria

Inclusion criteria

• Patients with a diagnosis of MPA or GPA independently of ANCA status,
• Patient aged of 18 years or older,
• Patients with newly-diagnosed disease or relapsing disease at the time of screening, with an inactive disease defined as a BVAS = 0,
• Patients receiving maintenance infusion of rituximab 500 mg at 6 and 12 months after the start of vasculitis induction
• Patients receiving 5-10 mg/day of prednisone at screening,
• Patient able to give written informed consent prior to participation in the study.
• At Inclusion visit day, patient must be between 5 and 10 mg/day prednisone and at randomization visit day (D1), patient must be at 5 mg/day prednisone

Exclusion criteria

• Patients with EGPA, or other vasculitides, defined by the ACR criteria and/or the Chapel Hill Consensus Conference,
• Patients with vasculitis with active disease defined as a BVAS >0,
• Patients with acute infections or chronic active infections (including HIV, HBV or HCV),
• Patients with active cancer or recent cancer (<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment,
• Pregnant women and lactation. Patients with childbearing potential should have reliable contraception for the all duration of the study,
• Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol,
• Patients included in other investigational therapeutic study within the previous 3 months,
• Patients suspected not to be observant to the proposed treatments,
• Patients who have white blood cell count ≤4,000/mm3,
• Patients who have platelet count ≤100,000/mm3,
• Patients who have ALT or AST level greater than 3 times the upper limit of normal that cannot be attributed to underlying MPA-GPA disease,
• Patients unable to give written informed consent prior to participation in the study.
• Patients with contraindication to use rituximab,

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Prevention

Study locations

France · 45 centers

• CHU Amiens-Hôpital Nord — Amiens
• CHU Angers — Angers
• Clinique Rhône-Durance — Avignon
• Hôpital Jeanne d'Arc — Bar-le-Duc
• Hôpital Avicenne — Bobigny
• Hôpital La Cavale Blanche — Brest
• Hôpital Louis Pradel — Bron
• CHU de Caen - Cote de Nacre — Caen
• … and 37 more centers

Identifiers

NCT: NCT03290456 · 69HCL17_0020

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗